Akoya BioSciences, Inc.

Good day, and welcome to the Akoya Biosciences second quarter 2023 earnings conference call. At this time, all participants are in listen-only mode. After the speaker's presentation, there will be a question and answer session. As a reminder, this call is being recorded. I would like to turn the call over to Priyam Shah, Head of Investor Relations at Akoya Biosciences.

You may begin. Thank you, Operator, and thank you to everyone who is joining us today on this call.

I'm Priyam Shah, Head of Investor Relations at Akoya Biosciences. On the call today, we have Brian McElligan, Chief Executive Officer, and Johnny Eck, Chief Financial Officer. Earlier today, Akoya released financial results for the second quarter into June 30th, 2023. A copy of the press release is available on the company's website. Before we begin, I'd like to remind you that management will make statements during this call that include forward-looking statements, within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements contained in this call that relate to expectations or predictions of future events, results, or performance are forward-looking statements. Actual results may differ materially from those expressed or implied in the forward-looking statements due to a variety of factors. For a list and description of the risks and uncertainties associated with the COIS business, please refer to the risks identified in our filings with the U.S. Securities and Exchange Commission, including in the risk factors section of our annual report on Form 10-K for the year ended December 31st, 2022, filed on March 6th, 2023, and subsequent filings with the SEC, including our quarterly report on Form 10-Q for the second quarter ended June 30th, 2023, filed today, August 7th, 2023. We urge you to consider these factors and you should be aware that these statements are considered estimates only and are not guaranteed a future performance. This conference call contains time-sensitive information and is accurate only as of the live broadcast today, August 7th, 2023. ACOIA disclaims any intention or obligation except as required by law to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This audio portion of this call will be archived in the Investors section of our website later today under the heading Events. PCOYA plans to participate in several upcoming investor conferences this quarter, including the Canaccord Genuity Growth Conference, UBS MedTech Tools and Genomics Summit, and the Morgan Stanley Healthcare Conference. Details can be found under events on our investor section of our website. And with that, I will now turn the call over to Brian.